Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL Therapy in Metastatic Melanoma
NCT03166397Phase 2Recruiting
- Sponsor
- Sheba Medical Center
- Start
- Jun 2017
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of GC101 TIL + pembrolizumab in melanoma, sponsored by Sheba Medical Center. Started Jun 2017; status: recruiting.
02
Drugs
GC101 TIL + pembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03166397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03166397.